Halozyme Therapeutics, Inc. (HALO) Reaches $20.68 After 3.00% Up Move; Luxoft Holding, Inc. (LXFT) Covered By 7 Bullish Analysts Last Week

December 13, 2017 - By Peter Erickson

Among 11 analysts covering Luxoft Holding (NYSE:LXFT), 7 have Buy rating, 1 Sell and 3 Hold. Therefore 64% are positive. Luxoft Holding had 33 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Luxoft Holding, Inc. (NYSE:LXFT) has “Sell” rating given on Thursday, September 7 by Credit Suisse. On Thursday, October 12 the stock rating was maintained by Cowen & Co with “Buy”. The stock has “Buy” rating by UBS on Thursday, November 12. Cowen & Co upgraded the shares of LXFT in report on Monday, December 19 to “Outperform” rating. The firm has “Outperform” rating given on Friday, January 6 by Wedbush. UBS maintained it with “Buy” rating and $68 target in Tuesday, July 28 report. Sterne Agee CRT initiated it with “Buy” rating and $60 target in Thursday, March 24 report. KeyBanc Capital Markets maintained the stock with “Hold” rating in Thursday, September 28 report. The firm has “Overweight” rating given on Tuesday, December 5 by KeyBanc Capital Markets. Monness Crespi & Hardt initiated Luxoft Holding, Inc. (NYSE:LXFT) rating on Wednesday, September 9. Monness Crespi & Hardt has “Buy” rating and $75 target. See Luxoft Holding, Inc. (NYSE:LXFT) latest ratings:

05/12/2017 Broker: Pivotal Research Rating: Buy New Target: $70.0
05/12/2017 Broker: KeyBanc Capital Markets Old Rating: Sector Weight New Rating: Overweight Upgrade
20/11/2017 Broker: UBS Rating: Neutral Old Target: $51 New Target: $55 Maintain
12/10/2017 Broker: Cowen & Co Rating: Buy New Target: $63.0 Maintain
28/09/2017 Broker: KeyBanc Capital Markets Rating: Hold Maintain
07/09/2017 Broker: Credit Suisse Rating: Sell New Target: $43.0 Downgrade
14/08/2017 Broker: Berenberg Rating: Buy New Target: $60.0000
11/08/2017 Broker: Wedbush Rating: Hold New Target: $50.0000 Downgrade
11/08/2017 Broker: Cowen & Co Rating: Buy New Target: $63.0000 Maintain
11/08/2017 Broker: UBS Rating: Hold New Target: $66.0000

The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a huge mover today! The stock increased 5.67% or $1.11 during the last trading session, reaching $20.68. About 988,072 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 44.89% since December 13, 2016 and is uptrending. It has outperformed by 28.19% the S&P500.The move comes after 9 months positive chart setup for the $2.92B company. It was reported on Dec, 13 by Barchart.com. We have $21.30 PT which if reached, will make NASDAQ:HALO worth $87.51 million more.

Luxoft Holding, Inc., together with its subsidiaries, provides software development services and IT solutions to multinational firms primarily in Europe and the United States. The company has market cap of $1.79 billion. It offers application software development, software architecture design, performance engineering, optimization and testing, process consulting, and software quality assurance services; functional specification and mock-up, product design, engineering, automated testing, maintenance, support, and performance engineering services; and IT strategy, software engineering process, and data security consulting services. It has a 32.2 P/E ratio. The companyÂ’s products and platforms include Teora, a suite of developer tools designed to enable automotive human machine interface developers build the logic of their user interface; Populus, a tool chain for HMI design and development, and the deployment of automotive user interfaces for distributed embedded systems; and AllView, a user-experience demonstrator that links instrument cluster, head unit, head-up display, and mobile devices.

The stock decreased 0.19% or $0.1 during the last trading session, reaching $53.45. About 35,431 shares traded. Luxoft Holding, Inc. (NYSE:LXFT) has risen 10.58% since December 13, 2016 and is uptrending. It has underperformed by 6.12% the S&P500.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company has market cap of $2.92 billion. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. It currently has negative earnings. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Investors sentiment decreased to 1.26 in 2017 Q2. Its down 0.76, from 2.02 in 2017Q1. It dived, as 16 investors sold Halozyme Therapeutics, Inc. shares while 30 reduced holdings. 28 funds opened positions while 65 raised stakes. 119.22 million shares or 5.94% more from 112.53 million shares in 2017Q1 were reported. 407,884 are held by Goldman Sachs Group Inc. Metropolitan Life Communication New York owns 74,477 shares. Orbimed Advsr Limited Liability Corporation invested in 350,000 shares. State Common Retirement Fund invested in 750,041 shares or 0.01% of the stock. Ameritas Invest Prns accumulated 9,416 shares or 0.01% of the stock. Morgan Stanley reported 0% stake. Endurant Capital Mngmt Lp reported 136,900 shares. D E Shaw Inc reported 11,054 shares. Moore Cap Limited Partnership invested 0.04% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Synovus Financial invested in 0.01% or 36,156 shares. Nj State Employees Deferred Compensation Plan has 0.35% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 145,000 shares. Dupont Cap Mngmt holds 19,543 shares. Doheny Asset Management Ca reported 104,825 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 5,105 shares in its portfolio. Proshare Lc holds 0.01% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 82,187 shares.

Among 8 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Halozyme Therapeutics has $27 highest and $12 lowest target. $20.33’s average target is -1.69% below currents $20.68 stock price. Halozyme Therapeutics had 18 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Overweight” rating by Barclays Capital on Tuesday, September 22. The company was maintained on Wednesday, February 24 by Barclays Capital. The stock has “Outperform” rating by Wells Fargo on Friday, December 4. JMP Securities maintained the shares of HALO in report on Wednesday, March 9 with “Market Outperform” rating. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Market Perform” rating given on Friday, September 15 by BMO Capital Markets. The firm earned “Buy” rating on Wednesday, August 9 by Piper Jaffray. On Wednesday, November 8 the stock rating was maintained by BMO Capital Markets with “Market Perform”. The company was initiated on Wednesday, November 18 by Citigroup. The company was maintained on Thursday, September 14 by Piper Jaffray. As per Thursday, November 3, the company rating was initiated by Deutsche Bank.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>